Webinar on demand
Webinar on demand
High-content analysis of disease models and toxicology studies using C. elegans
High-content analysis of disease models and toxicology studies using C. elegans
vivoChip - The next generation of microfluidic screening solutions
vivoChip enables rapid immobilization and high-resolution imaging of C. elegans
High-resolution imaging of entire germline organization
vivoChip-96x: The first large-scale screening platform for C. elegans
Webinar on demand
Webinar on demand
High-content analysis of disease models and toxicology studies using C. elegans
High-content analysis of disease models and toxicology studies using C. elegans
Newormics is the developer of the first in vivo imaging and screening platform for C. elegans and other small model organisms, providing both high-content data and high-throughput speeds.
We use this technology to provide our customers with toxicology screening services, and systems for performing their own studies.
Enabling high-content imaging of C. elegans at high-speeds
Simple control of vivoChip microfluidics
In vivo multi-parametric toxicity analysis
High-resolution imaging of ~4000 C. elegans at high-speeds
Small scale vivoChip technology designed for academic labs
Newormics awarded SBIR Phase II grant from NIMH
Newormics is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) for the continued development of the company’s in vivo imaging and screening technologies.
Newormics Announces Intent to Grant Utility Patent on the vivoChip by the European Patent Office
Newormics LLC, a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models, announced that the European Patent Office (EPO) intends to grant a patent covering the vivoChip® technology, the device design and use for C. elegans studies.
Evan Hegarty, co-founder, received his M.S. in Mechanical Engineering at The University of Texas at Austin while developing the technology and IP that lead to the launch of Newormics, LLC. As the Director of Manufacturing and Product development, and Principal Investigator of NIH SBIR grants at Newormics, Evan is responsible for development of all chip and system designs, creating production schedules, optimizing production methods, managing team members, identifying customer needs, developing future products, and reinforcing GLP and GMP.
A professor with dual appointments in Mechanical Engineering and Biomedical Engineering at The University of Texas at Austin, Dr Ben-Yakar’s research focuses on the creation of imaging technologies and novel laser surgery with high precision. Educated at Stanford and the Technion in Israel, with post-doctoral study at Harvard, and using her NIH Director’s Transformative Research Award, Dr Ben-Yakar began the research that has culminated in the launch of Newormics, LLC
Dr. Yunki Im is a molecular geneticist with expertise in autophagy, mitophagy, unfolded protein response, post-translational modifications (sumoylation and ubiquitination), and mitochondrial biology applied to study neurodegenerative disease and cardiac vascular disease in C. elegans and mice. He was educated at GIST in Korea, with post-doctoral study at University of Rochester, NY.
Jacob Moore completed his master’s and PhD in mechanical engineering at the University of Texas at Austin before joining the Newormics team. From his experimental research in the gas turbine industry, he developed a hands-on expertise in thermal/fluids systems that he is applying to chip and system designs. In addition, he is using his automated laboratory measurement experience to mature automation designs using Newormics technology.
Dr. Adam Laing is a molecular and cellular biologist educated at the University of Edinburgh, and leads the Research and Development activities of Newormics. He is responsible for testing and characterizing the new devices and imaging methods, and development of toxicology and drug screening assays in C. elegans as well as tissue organoids.
Dr. Lento is a serial COO/VPO executive for life science startups with broad skills in pharmaceuticals, medical devices, and diagnostics. With a unique background of equal parts government, public and private sector service, Dr. Lento holds a PhD in Biochemistry and additional credentials in Drug Evaluation, Pharmaceutical Sciences, and Corporate Governance.